Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | AB521 + SSGJ-707 |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| AB521 | AB-521|AB 521|casdatifan | HIF2A Inhibitor 6 | AB521 selectively inhibits HIF-2alpha, potentially resulting in downregulation of HIF-2alpha target genes and antitumor activity (Ann Oncol 33 (2022): S21). | |
| SSGJ-707 | PF-08634404|SSGJ 707|SSGJ707|PF08634404|PF 08634404 | PD-L1/PD-1 antibody 138 VEGF Antibody 17 | SSGJ-707 (PF-08634404) is a bispecific antibody that targets PDCD1 (PD-1) and VEGF, which potentially decreases tumor growth (Journal for ImmunoTherapy of Cancer 2025;13, Suppl_3). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07227415 | Phase Ib/II | SSGJ-707 AB521 + SSGJ-707 Ipilimumab + SSGJ-707 Axitinib + SSGJ-707 | Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer | Recruiting | USA | ESP | DEU | AUS | 2 |